Cyclic Dinucleotide Modulators for STING Pathway Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory, allergic, autoimmune diseases, infectious diseases, and cancer lack effective immunomodulatory strategies that can modulate the STING pathway to induce type I interferons and cytokines, which are crucial for immune response modulation.
Innovation Solution
Development of specific compounds that bind to STING, inducing type I interferons and cytokines, or acting as antagonists, to treat diseases by modulating the STING pathway, including the use of pharmaceutical compositions and combinations with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for inflammatory, allergic, autoimmune diseases, infectious diseases, and cancer, then existing therapeutic approaches are maintained, but effective immunomodulatory strategies that can modulate the STING pathway to induce type I interferons and cytokines are lacking
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of cyclic dinucleotides to create analogues with enhanced STING pathway modulation capability. Specifically, the invention alters the nucleotide structure (changing base pairs, sugar moieties, or phosphate groups) to optimize binding affinity and biological activity, thereby improving the reliability of immunomodulation while maintaining pathway adaptability
Solution Approach 2:
The patent uses cyclic dinucleotide analogues as intermediary molecules that mediate between the administered compound and the STING pathway. These analogues serve as the active intermediaries that directly bind to and modulate STING, inducing type I interferons and cytokines, thus bridging the gap between current treatments and effective immunomodulation
2Reliability
If compounds that bind to STING and induce type I interferons and cytokines are developed, then immune response modulation is enhanced, but the complexity of compound development and pharmaceutical composition increases
Solution Approach 1:
The patent applies segmentation by dividing the complex compound development into systematic structural modifications of cyclic dinucleotides. The invention segments the molecule into modifiable components (bases, sugars, phosphates) and systematically varies these segments to achieve desired STING modulation, thereby managing development complexity while enhancing immune response modulation
Solution Approach 2:
The patent achieves universality by designing cyclic dinucleotide analogues that can serve multiple functions: they act as STING agonists, induce type I interferons, stimulate cytokine production, and can be formulated as pharmaceutical compositions. This multi-functionality reduces the need for separate compounds for different immunomodulatory purposes, simplifying the overall development complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively treat inflammatory, allergic, autoimmune diseases, infectious diseases, and cancer by enhancing the immune response through STING pathway modulation, offering potential as vaccine adjuvants and therapeutic agents.
Implementation Method 1
Certain compounds of the invention have been shown to bind to STING and to induce type I interferons and other cytokines
Data Source
AI summary
A compound of formula (I) or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer and as vaccine adjuvants